5 HT |
5-hydroxytryptamine (serotonin) |
ABFat |
Android body fat |
ACh |
Acetylcholine |
ADHD |
Attention-deficit/hyperactivity disorder |
AhR |
Aryl hydrocarbon receptor |
ASD |
Autism spectrum disorder |
BAI |
Beck Anxiety Inventory |
BCFAs |
Branched short-chain fatty acids |
BDI |
Beck Depression Inventory |
BDNF |
Brain-derived neurotrophic factor |
CFB |
Cytophaga–Flavobacterium–Bacteroides |
CFU |
Colony Forming Unit |
CNS |
Central nervous system |
CRP |
C-reactive peptide |
FFARs |
Short-chain fatty acid receptors/free fatty acids receptors |
GABA |
Gamma-aminobutyric acid |
GAD |
Generalized Anxiety Disorder |
GBFat |
Gynoid body fat |
GDM |
Gestational diabetes mellitus |
GIT |
Gastrointestinal tract |
Glu |
Glutamate |
GPRs |
G-protein-coupled receptors |
GRAS |
Generally Recognized as Safe |
HADS |
Hospital Anxiety and Depression Scale |
HAM-A |
Hamilton anxiety rating scale |
HAM-D |
Hamilton Depression Rating Scale |
HCAR |
Hydroxycarboxylic acid receptor |
HDACs |
Histone deacetylases |
HPA axis |
Hypothalamic–pituitary–adrenal axis |
IBD |
Inflammatory bowel disease |
IBS |
Irritable bowel syndrome |
IGF-1 |
Insulin-like growth factor-1 |
II |
Impedance index |
IL |
Interleukin |
IMAT |
Intermuscular adipose tissue |
LPS |
Lipopolysaccharide |
MADRS |
Montgomery–Åsberg Depression Rating Scale |
MAFLD |
Metabolic-associated fatty liver disease |
MDD |
Major depressive disorder |
MetS |
Metabolic syndrome |
NAFLD |
Non-alcoholic fatty liver disease |
NF-ĸB |
Nuclear factor-ĸB |
PAMP |
Pathogen-associated molecular patterns |
PANSS |
Positive and Negative Syndrome Scale |
PYY |
Peptide YY |
RTC |
Double-blind, randomized, placebo-controlled trials |
SCFAs |
Short-chain fatty acids |
SIBO |
Small intestinal bacterial overgrowth |
T2D |
Type 2 diabetes mellitus |
TAU |
Treatment as usual |
TBFat |
Total body fat |
TBLean |
Total body lean |
TGF-α |
Transforming growth factor α |
TLRs |
Toll-like receptors |
TSH |
Thyroid-stimulating hormone |
WHO |
World Health Organization |